Table 1 Full inclusion and exclusion criteria used to screen prospective publications

1. Studies that include resected stage II and III colon cancers

2. Study intervention includes adjuvant chemotherapy or molecular/genomic biomarkers guiding adjuvant chemotherapy patient selection

3. Studies evaluating different adjuvant chemotherapy strategies such as chemotherapy vs. no chemotherapy, use of specific regimens, addition/absence of oxaliplatin and duration of chemotherapy

4. Model- or trial-based health economic evaluations such as cost–benefit and effectiveness analyses, costing studies, budget impact analyses

1. Studies that exclusively focus on rectal cancer (including neoadjuvant and/or surgical strategies)

2. Studies that includes or exclusive to other cancer types aside from colon (including anal cancer)

3. Studies pertaining to surgical strategies and/or neoadjuvant therapy

4. Studies evaluating non-consensus guideline supported adjuvant therapy or medications (including intraportal chemotherapy, adjuvant radiotherapy and chemoradiotherapy)

5. Studies pertaining to screening, prevention, surveillance and/or treatment of metastatic disease

6. Studies exclusively evaluating cost of illness

7. Studies exclusively evaluating strategies to limit or avoid toxicities

8. Studies exclusively evaluating quality of life or evaluation of health utility values without consideration of costs

9. Studies exclusively evaluating use of molecular and genomic markers without consideration of costs

10. Studies that compare hospital-based to home-based chemotherapy delivery

11. Reviews, commentaries, letters and abstracts